Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI
|
|
- Grace Norman
- 5 years ago
- Views:
Transcription
1 Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI
2 2 Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making Lucia Helena De Oliveira New Vaccines Advisor, Immunization Unit/FGL, Pan American Health Organization/World Health Organization Barbara Jauregui International Consultant, Comprehensive Family Immunization Unit, Pan American Health Organization/World Health Organization Introduction Biotechnological advances in recent decades have resulted in the proliferation of new vaccines at an unprecedented pace. The Region of the Americas has been at the forefront of the introduction of new vaccines in the national immunization schedules, particularly in connection with the introduction of the rotavirus, pneumococcus, and human papillomavirus (HPV) vaccines. 1,2 In general, new vaccines have demanded more years of research for their development and have frequently required the use of new and more complex technologies, which make them more expensive. 3 To minimize the inequalities resulting from the lack of access to vaccines in developing countries, it is necessary to support the decision-making process with a broader and more solid evidence base to make a case for such investment. 4 Consequently, the Ministries of Health in Latin America and the Caribbean (LAC) adopted a Pan-American Health Organization (PAHO) resolution to call for broader evidence to be used for informed decision-making on the introduction of vaccines with the technical support of PAHO. They urged Member States to mobilize additional resources to support analyses for the introduction of new vaccines. 5 VACCINOLOGY IN LATIN AMERICA
3 De Oliveira and Jauregui 3 Figure 1. Universal Introduction of the RV and PCV Vaccines in the EPI, Region of the Americas, 2016 BOTH PCV & RV 1. Argentina 2. Bolivia 3. Brazil 4. Cayman Islands 5. Colombia 6. Dominican Republic 7. Ecuador 8. El Salvador 9. Guatemala 10. Guyana 11. Honduras 12. Mexico 13. Nicaragua 14. Panama 15. Paraguay 16. Peru 17. United States of America 18. Venezuela ONLY PCV 1. Aruba 2. Bahamas 3. Barbados 4. Bermuda 5. Bonaire 6. Canada 7. Chile 8. Costa Rica 9. Curacao 10. French Guiana 11. Guadeloupe 12. Martinique 13. Saba 14. St. Eustatius 15. Trinidad & Tobago 16. Uruguay ONLY RV 1. Haiti PCV: 34 countries & territories /// RV: 19 countries & territories Source: PAHO/WHO country reports
4 4 Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making Criteria for Decision-Making The decision-making process for the introduction of a new vaccine is complex and should be undertaken with absolute caution and responsibility to guarantee a successful and sustainable introduction in the long term. Ultimately, upon introduction of a vaccine in the national immunization schedule, withdrawal is not a good practice given its ethical, political and social implications. To ensure that vaccine introductions achieve the greatest sustainable impact, experts have identified three essential factors Decisions should be nationally based, since countries have different burdens of disease, infrastructure, and budget. 2. Scientific evidence used to support decisions must be broad based, including cost-effectiveness and financial sustainability measures. 3. Infrastructure must be in place to support nationally based decision-making, including a National Immunization Technical Advisory Group (NITAG) or another independent advisory body. Additionally, based on vaccine introduction guidelines issued by the Word Health Organization (WHO), PAHO developed the Field Guide for the Introduction and Implementation of New Vaccines, describing the various criteria to be taken into account when considering adding a new vaccine to the national schedule. 3,7 These can be broken down into political and technical considerations, and program and feasibility considerations. Political and Technical Considerations Political and technical considerations lay the foundational support and scientific evidence upon which a recommendation to introduce or to not introduced a health strategy will be based. Beyond the political considerations which fall under the responsibility of high level authorities, all technical aspects are usually reviewed and discussed by the National Immunization Technical Advisory Group (NITAG) or similar national committee. This important independent advisory body makes technical recommendations to the Ministry of Health on the best control measures against the disease to be prevented. Public Health Priority. The Ministries of Health first assess if the vaccine-preventable disease is a public health priority in their country. Therefore, the opinion of various key stakeholders needs to be established and documented through qualitative evaluations. The more awareness there is about the problem, the broader the acceptance of the vaccine introduction will be, and strategies for awareness raising are often times the first step in the policymaking process. Importantly, awareness raising requires supporting data and evidence about the magnitude of the problem, and this is where burden of disease comes into play. VACCINOLOGY IN LATIN AMERICA Burden of Disease. To make an informed decision, it is essential to be aware of the magnitude of the disease burden intended to reduce. This requires national studies on incidence, prevalence, disability, hospital admissions, and mortality. Ideally, this information can be obtained through surveillance data and/or special studies. When country-level research and surveillance data are available, disease burden is easily recognized, facilitating policy development. On the other hand, when there is a lack of sufficient national-level data, disease burden is difficult to estimate, and policymakers are left with neighboring country or even broad regional or international estimations to inform their decisions.
5 De Oliveira and Jauregui 5 Vaccine Efficacy and Safety. Vaccine efficacy and safety are established in clinical trials under ideal conditions prior to the licensing of the vaccine and during the post-marketing phase. This critical piece of information is considered by Ministries of Health to determine the potential added value of the intervention as an effective and safe public health strategy. Comparison with Other Interventions (Including Other Vaccines). For some diseases, there are a number of vaccines to select from and other non-vaccination interventions available. Comparison of the various control interventions requires the proper analysis level for each of them. The key aspects to consider in a comparative analysis are burden of disease, effectiveness, costs of each intervention, and cost-effectiveness results. 8,9 Comparisons between interventions require the use of national-level data to the extent possible, since there is great variability in disease burden, immunization program and healthcare costs, and even vaccine effectiveness data, where it exists. Economic and Financial Criteria. Assessment of the economic and financial implications of the new vaccines provides valuable information for the decision-making process of governments and their partners. Different types of economic analyses assess health interventions, including: cost analysis, cost-minimization analysis, cost-benefit analysis, cost-effectiveness analysis and return on investment analysis. These types of analyses are described further in the chapter, Stronger Immunization Policy in Latin America and the Caribbean: Vaccine impact, costs and cost-effectiveness evidence. Program and Feasibility Considerations Program and feasibility considerations are related to the characteristics of the product to be introduced. They need to be assessed by technical experts since they imply an analysis of the functioning, logistics, supply, performance, and delivery of the vaccine by the immunization program. These considerations often have the final say in the decision-making process, since sometimes technically sound recommendations cannot be put in practice in imperfect real-world conditions. Vaccine Characteristics and Supply. Countries should determine if the vaccine characteristics, administration route, and formulation available in the market is adequate for the national program or if problems with the program logistics or functioning can be anticipated, including additional cold chain capacity requirements, or the need to change the delivery strategy, among others. Likewise, vaccine supply needs to be considered to ensure an uninterrupted offer of the product to the country s population. Performance of the Immunization Program. The introduction of a new vaccine may increase community demand and/or weaken the immunization program. Therefore, prior to the introduction of a new vaccine, it is important to assess the current performance of the program and work on the aspects that need to be strengthened or prepared in advance for a successful introduction.
6 6 Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making Decision-Making Process The criteria above constitute the necessary elements to be considered by the national immunization program manager to justify a preliminary technical decision. This decision should also consider discussions among the interdisciplinary groups of the Ministries of Health that are relevant to the health problem being addressed. This includes the teams performing cost-effectiveness studies with PAHO s ProVac tools, as presented in greater detail in the chapter, Stronger Immunization Policy in Latin America and the Caribbean: Vaccine impact, costs and costeffectiveness evidence. This analysis usually concludes with a two-way decision: recommend the introduction of the new vaccine or defer its introduction. Often times, however, decisions to scale up or change a vaccination strategy are also made, with the aim to improve vaccination coverage and the performance of the program. Regional Evaluation of New Vaccine Introduction in Latin America A regional study performed in 2009 analyzed the existence and functioning of the national immunization technical advisory groups in the Americas as components of the decision-making process on the introduction of new vaccines. 10 Of the 29 countries that returned the questionnaire, 17 reported that they had a NITAG. The participating countries underscored the need to strengthen the immunization policy decision-making process by: Creating or strengthening the existing NITAG; Improving coordination among stakeholders of the decision-making process; Increasing political commitment for immunization; Strengthening national data collection systems; Securing vaccine financing; and Generating economic evaluations. Since then, countries in the Americas have been making steady though variable progress on these dimensions. These conditions allow national governments to make better technical decisions about immunization programs, take responsibility for helping to pay for and distribute vaccines, and reduce the gap between developed countries and developing countries in the prevention of cases and deaths due to vaccine-preventable diseases. 11 VACCINOLOGY IN LATIN AMERICA To improve knowledge and promote understanding of the new vaccine introduction process in the Region of Latin America, in 2012 a systematic qualitative assessment was performed with specific emphasis on the rotavirus vaccine (RV) and the pneumococcal conjugate vaccine (PCV.) 1 The decision-making process, the existing program structure, and the key factors that influenced the introduction of new vaccines were assessed, including national data on morbidity and mortality available and considered before the introduction of vaccines, sources of financing and mechanisms for vaccine introduction, implementation challenges and evaluation of vaccine impact. The countries included were Bolivia, Brazil, Nicaragua, Peru, and Venezuela. Their decision-making process was assessed through interviews with key participants in each country and a systematic review of published data, gray literature, official technical documents and country-specific health indicators.
7 De Oliveira and Jauregui 7 The study results showed the potential of new vaccines to reduce mortality, as established in the Millennium Development Goal Number 4, was an important consideration that led to the introduction of vaccines in all of the countries assessed. Additionally, other key components of the decision-making process in these countries included availability of funds, existence of adequate evidence for vaccine introduction, and the feasibility of sustained financing. Finally, the study concluded that the decision-making process in the countries assessed does not follow a systematic approach. However, available evidence on efficacy, potential impact, and cost-effectiveness, even without local data, are significant elements in the decision-making process for the introduction of vaccines in Latin America. Conclusions For the introduction of new vaccines to be successful several criteria should be considered and agreed amongst various stakeholders. Latin America and the Caribbean countries have introduced new vaccines at a very high pace, and in doing so, some countries have followed the criteria described in this chapter more rigorously and comprehensively than other countries. As new and more expensive vaccines continue to emerge and as the national immunization programs require an increasingly higher budget, it will become important to count on the scientific evidence base to achieve successful and sustained introductions of new vaccines. The creation and strengthening of NITAGs allow for a broad and independent evaluation of all the vaccinerelated technical evidence under consideration. Lastly, quality national-level data on vaccine-preventable diseases is a critical component to be able to support the decision-making process within the national context.
8 8 Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making References 1. Oliveira L, Toscano C, Sanwogou N, et al. Documentación sistemática de la introducción de nuevas vacunas en países seleccionados de la Región de América Latina. Vaccine 2013; 31S: C Oliveira L, Danovaro-Holliday C, Ruiz Matus C and Andrus JK. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev. Vaccines 2008; 7(3), World Health Organization. Vaccine Introduction Guidelines. Adding a vaccine to a national immunization program: decision and implementation. Geneva, Switzerland: WHO, Andrus J, Dietz V, Fitzsimmons J, et al. Accelerating Policy, Deployment and Access to New and Underutilized Vaccines in Developing Countries. Harvard Health Policy Review 2006; 7(2): PAHO Resolution. Regional Strategy for Sustaining National Immunization Programs in the Americas, 58th Session of the Regional Committee in Washington DC, September Andrus J, Toscano C, Lewis M, et al. A Model for Enhancing Evidence-based Capacity to Make Informed Policy Decisions on the Introduction of New Vaccines in the Americas: PAHO s Provac Initiative. International Observer 2007; 122; PAHO. Epidemiological Surveillance of Diarrheal Diseases due to Rotavirus: Field Guide. Washington DC: PAHO; Jauregui B, Sinha A, Clark A, et al. Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction. Vaccine 2011; 29(5): Janusz C, Jauregui B, Sinha A, et al. Performing Country-led Economic Evaluations to Inform Immunization Policy. Value in Health Regional Issues 2012; 1(248): Burns JE, Mitrovich RC, Jauregui B, et al. Descriptive analysis of immunization policy decision making in the Americas. Pan Am J Public Health 2009; 26(5): Andrus J, Jauregui B, Oliviera L, Matus C. Challenges to Building Capacity for Evidence-Based New Vaccine Policy in Developing Countries. Health Affairs 2011; 26(30):1 8. VACCINOLOGY IN LATIN AMERICA
Regional Update Pandemic (H1N1) 2009
Regional Update Pandemic (H1N1) 2009 (September 18, 2009-22 h GMT; 17 h EST) Update on the Qualitative Indicators For Epidemiological Week 36 (EW 36), from 6 September to 12 September, 17 countries reported
More informationProgress Toward Rubella and Congenital Rubella Syndrome Elimination in the Western Hemisphere,
1 Introduction: Progress Toward Rubella and Congenital Rubella Syndrome Elimination in the Western Hemisphere, 2003-2008 1 Enhanced measles elimination activities in the Region of the Americas during the
More informationPandemic (H1N1) (August 28, h GMT; 12 h EST) Update on the qualitative indicators
Regional Update Pandemic (H1N1) 29 (August 28, 29-17 h GMT; 12 h EST) Update on the qualitative indicators For Epidemiological Week 33 (EW 33), from 16 August to 22 August, 22 countries reported updated
More informationRegional Update Pandemic (H1N1) 2009
Regional Update Pandemic (H1N1) 2009 (September 04, 2009-22 h GMT; 17 h EST) Update on the Qualitative Indicators For Epidemiological Week 34 (EW 34), from 23 August to 29 August, 20 countries reported
More informationPandemic (H1N1) (August 14, h GMT; 12 h EST) Update on the Qualitative Indicators
Regional Update Pandemic (H1N1) 2009 (August 14, 2009-17 h GMT; 12 h EST) Update on the Qualitative Indicators For epidemiological week 31 (EW 31, August 2 to August 8) 17 countries have reported updated
More informationTaking vaccine effectiveness into public health decision making: The ProVac Example
http://www.paho.org/provac Taking vaccine effectiveness into public health decision making: The ProVac Example Evaluating dengue effectiveness workshop June 12 th, 2014 Washington, DC Cara Bess Janusz
More informationStrengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative
http://www.paho.org/provac Strengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative Cara Bess Janusz Immunization, PAHO 1 st Regional Dengue Symposium 3-4 November
More informationHepatitis B and C in the Spotlight: A public health response in the Americas. Key Messages
2017 highlights Hepatitis B and C in the Spotlight: A public health response in the Americas Key Messages Regarding the national structures developed to support the response to the viral hepatitis epidemics,
More informationRegional Update Pandemic (H1N1) 2009 (March 15, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (March 15, 2010-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More informationIntroduction to the ProVac Initiative
Introduction to the ProVac Initiative E-toolkit training module Nathalie El Omeiri, PAHO/WHO, Washington D.C. Family, Health Promotion and Life Course, Immunization unit, elomeirin@paho.org Contents of
More informationSustaining Immunization in Developing Countries: The Future We Make
Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication
More informationdeveloping countries in Latin America?
. How have rotavirus vaccines worked in developing countries in Latin America? Brendan Flannery, Pan American Health Organization, Brazil and Lúcia De Oliveira, Immunization Unit/FCH, Washington, DC 9th
More informationRegional Update Pandemic (H1N1) 2009 (January 19, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (January 19, - 17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More informationDR. CLAUDINA E. CAYETANO REGIONAL MENTAL ADVISOR Pan-American Health Organization/ World Health Organization
DR. CLAUDINA E. CAYETANO REGIONAL MENTAL ADVISOR Pan-American / World Outline Facts and Figures Suicide a major Public problem Suicide in the Americas Risk and Protective factors and related interventions
More informationRegional Update Pandemic (H1N1) 2009 (December 1, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (December 1, 2009-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More informationRegional Update Pandemic (H1N1) 2009 (July 31, h GMT; 17 h EST) Update on the Qualitative Indicators Epidemiological Week 29 intensity
Regional Update Pandemic (H1N1) 2009 (July 31, 2009-22 h GMT; 17 h EST). Update onn thhe t Quual lli iit tati iivve InndiI iicatorss As of Epidemiological Week 29 (EW 29, July 19 to 25) all the 35 countries
More informationRegional Update Pandemic (H1N1) 2009 (July 19, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 9 (July 19, - 17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza
More informationInfluenza Vaccine Use In the Americas
Influenza Vaccine Use In the Americas Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-i Alba Maria Ropero-Alvarez Comprehensive Family Immunization Unit PAHO/FGL/IM Global Vaccine and
More informationSpecial Topic. The ten leading causes of death in countries of the Americas
The ten leading causes of death in countries of the Americas Table 1: Country specific information on the ten leading causes of death in broad age groups, by sex, for the latest two or three data years
More informationRegional Update Pandemic (H1N1) 2009 (July 6, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 29 (July 6, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza
More informationInvestigating Disease Epidemics through Simulation with a focus on Chikungunya in the Americas
Investigating Disease Epidemics through Simulation with a focus on Chikungunya in the Americas Alexandra L. Stone and Jean C. Galan-Rivera Mentors: Dr. Jacob Oleson and Dr. Grant Brown ISIB 2015 University
More information50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September-1 October 2010 Agenda Item 4.17 27 September
More informationcountries do not have information available for this indicator.
Regional Update Pandemic (H1N1) 2009 (July 22, 2009-22 h GMT; 17 h EST) The data and information in this report will be updated on a weekly basis and available at: http://new.paho.org/hq/index.php?option=com_content&task=blogcategory&id=814&itemid=1206
More informationPerforming Country-led Economic Evaluations to Inform Immunization Policy: ProVac Experiences in Latin America and the Caribbean
VALUE IN HEALTH REGIONAL ISSUES 1 (2012) 248 253 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/vhri CONCEPTUAL ARTICLES Performing Country-led Economic Evaluations
More informationWORLD RADIOLOGY DAY 2013
WORLD RADIOLOGY DAY 2013 RADIOLOGY: FACING SOME MAJOR PUBLIC HEALTH CHALLENGES IN LAC: CANCER, CVDS, TB, MATERNAL AND INFANT MORTALITY November 8, 2013. Washington DC. USA Branka Legetic, Unit Chief a.i.,
More information50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September-1 October 2010 Provisional Agenda Item 4.10
More informationVaccine Decision-Making
Key Points Vaccine Decision-Making * Decisions on introducing new vaccines have long-term implications for immunization costs as well as logistics systems and service delivery. The choice of vaccine presentation
More informationOverview of the ProVac Initiative
Overview of the ProVac Initiative Updated Dec. 2017 Goal of the ProVac Initiative Strengthen evidence-based decision making on immunization to sustain and further the public health impact of immunization
More informationProgress Made in the Integration of EPI Costing and Planning
Volume XXXV Number 5 Immunize and Protect Your Family October 2013 Progress Made in the Integration of EPI Costing and Planning If we compare the situation of the Expanded Program on Immunization (EPI)
More informationOVERVIEW OF THE POLIO ERADICATION AND ENDGAME STRATEGIC PLAN AND THE topv TO bopv SWITCH
OVERVIEW OF THE POLIO ERADICATION AND ENDGAME STRATEGIC PLAN AND THE topv TO bopv SWITCH Dr. Karen Lewis-Bell Advisor, Immunization Switch Monitoring Training Jamaica, December 9, 2015 Presentation Outline
More informationRegional Update Pandemic (H1N1) 2009 (May 24, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (May 24, 2010-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More informationHPV Vaccines: Background and Current Status
HPV Vaccines: Background and Current Status Bogota, Colombia, 2007 Jon Kim Andrus, MD HPV and Cervical Cancer Evidence that HPV is essential: Documented molecular studies of cervical cancer Case-control
More informationSenior Management Team Meeting Target setting in Latin America
Senior Management Team Meeting Target setting in Latin America October 2006 Nancy Andrade-Castro RST Latin America Geneva/2006 For all enquiries, please contact Nancy Andrade-Castro, Acting Director for
More informationCervical Cancer Situation in Latin America and the Caribbean and PAHO/WHO Recommendations for the Way Forward
Cervical Cancer Situation in Latin America and the Caribbean and PAHO/WHO Recommendations for the Way Forward Silvana Luciani Advisor, chronic disease prevention and control project Pan American Health
More informationRegional Update Influenza (August 16, h GMT; 12 h EST)
Regional Update Influenza (August 16, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza
More informationB. PLAN OF ACTION FOR IMPLEMENTING THE GENDER EQUALITY POLICY
Page 7 B. PLAN OF ACTION FOR IMPLEMENTING THE GENDER EQUALITY POLICY Background 1. Member States approved the Pan American Health Organization s (PAHO) Gender Equality Policy during the 46th Directing
More informationChampioning Health: Sustainable Development and Equity. PAHO Strategic Plan
Championing Health: Sustainable Development and Equity PAHO Strategic Plan 2014-2019 PAHO Strategic Plan 2014-2019 While we celebrate important achievements, we recognize that much remains to be accomplished.
More informationCountry Length Discount Travel Period Anguilla All 20% off 08/24/11 12/15/11 Antigua All 20% off 08/24/11 12/15/11 Argentina All 20% off 08/24/11
Country Length Discount Travel Period Anguilla All 20% off 08/24/11 12/15/11 Antigua All 20% off 08/24/11 12/15/11 Argentina All 20% off 08/24/11 12/15/11 Aruba All 20% off 08/24/11 12/15/11 Australia
More informationREGIONAL STRATEGY AND PLAN OF ACTION FOR CERVICAL CANCER PREVENTION AND CONTROL IN LATIN AMERICA AND THE CARIBBEAN
REGIONAL STRATEGY AND PLAN OF ACTION FOR CERVICAL CANCER PREVENTION AND CONTROL IN LATIN AMERICA AND THE CARIBBEAN 525 Twenty-third Street, N.W. Washington, D.C. 20037 1 2 In response to the high incidence
More informationCD29/23 Page 2. (Eng.) EXPANDED PROGRAM ON IMMUNIZATION IN THE AMERICAS. Progress Report by the Director. 1. Background and Policy Basis
directing council PAN AMERICAN HEALTH ORGANIZATION regional committee WORLD HEALTH ORGANIZATION XXIX Meeting Washington, D.C. September-October 1983 XXXV Meeting INDEXEo L I I Provisional Agenda Item 23
More information20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus since April 2009.
B. UPDATE ON THE PANDEMIC (H1N1) 2009 CD50/INF/6 (Eng.) - 7 - Annex B Background 20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus
More informationREVELAC-i: Progress in measuring influenza vaccine effectiveness in Latin America and way forward
REVELAC-i: Progress in measuring influenza vaccine effectiveness in Latin America and way forward SARInet annual meeting, Punta Cana, May 23 2017 Nathalie El Omeiri On behalf of REVELAC-i network, Alba
More informationRubella and CRS Elimination in the Americas
Rubella and CRS Elimination in the Americas Jon Kim Andrus, MD Deputy Director, PAHO Rome, Italy 8-10 February 2012 Presentation Opportunities for a rubella elimimation initiative The impact of the initiative
More information42nd DIRECTING COUNCIL 52nd SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 42nd DIRECTING COUNCIL 52nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., 25-29 September 2000 Provisional Agenda Item 4.7 CD42/11 (Eng.)
More informationHealthy Caribbean 2012 Rallying for Action on NCDs
Healthy Caribbean 2012 Rallying for Action on NCDs Regional Strategy and Plan of Action for Cervical Cancer 27 May, 2012, Kingston, Jamaica Dr Tomo Kanda Advisor on Chronic Diseases & Mental Health PAHO
More informationASSESSMENT OF IMPACTS OF AIR POLLUTION ON HEALTH
ASSESSMENT OF IMPACTS OF AIR POLLUTION ON HEALTH Michal Krzyzanowski WHO ECEH Bonn Office 1 Exposure - Response Population X Exposure IMPACT ESTIMATE FOR POPULATION X Population X health status WHO Air
More informationUsing surveillance data to monitor impact of rotavirus vaccine. Lúcia De Oliveira Regional Advisor on New Vaccines IM/PAHO
Using surveillance data to monitor impact of rotavirus vaccine Lúcia De Oliveira Regional Advisor on New Vaccines IM/PAHO Main Topics Epidemiological surveillance of rotavirus in American Region Impact
More informationCervical Cancer Control in Latin America and the Caribbean ROUNDTABLE POLICY BRIEF. Dr Rolando Camacho Rodríguez
Cervical Cancer Control in Latin America and the Caribbean ROUNDTABLE POLICY BRIEF Dr Rolando Camacho Rodríguez ABBREVIATIONS CIN DIRAC HPV IAEA IARC LAC LEEP LMIC MoH NCCP NCI NGO PAHO RINC TEC VIA VIL
More information52nd DIRECTING COUNCIL 65th SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 52nd DIRECTING COUNCIL 65th SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, from 30 September to 4 October 2013 Provisional Agenda Item
More informationFigure 1: Case Distribution of Dengue Hemorrhagic Fever, in %, by subregion, *This includes cases of dengue with complications.
Regional Update on Dengue (17 March 2009) Situation of Dengue in the Americas, 2008 Dengue is an endemic disease in most of the countries of the Americas and, over the past 20 years, has shown sustained
More informationCurrent Status in Latin America
WHO International Consultation 15 to 17 October 2014 Munich, Germany JUSTIFICATION OF THE USE OF CT FOR INDIVIDUAL HEALTH ASSESSMENT OF ASYMPTOMATIC PEOPLE Current Status in Latin America Gloria Soto Giordani
More informationViolence against women and girls in LAC and recent health system mandates
Violence against women and girls in LAC and recent health system mandates ALESSANDRA GUEDES Regional Advisor, Family Violence PAHO/WHO, Washington, DC December 5, 2016 Outline of the presentation Violence
More informationLessons Learned and Best Practices of Achieving and Maintaining Measles and Rubella Elimination in the Americas
Lessons Learned and Best Practices of Achieving and Maintaining Measles and Rubella Elimination in the Americas Jon Kim Andrus, MD Deputy Director, PAHO Rome, Italy 8-10 February, 2012 Presentation Outline
More information50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September -1 October 2010 CD50/DIV/9 ORIGINAL: SPANISH
More information132nd SESSION OF THE EXECUTIVE COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 132nd SESSION OF THE EXECUTIVE COMMITTEE Washington, D.C., USA, 23-27 June 2003 Provisional Agenda Item 4.11 CE132/19 (Eng.) 28 April 2003 ORIGINAL:
More informationFIRST CONFIRMED CASE OF IMPORTED ZIKA VIRUS IN HOUSTON, TEXAS. Preventing Transmission
FIRST CONFIRMED CASE OF IMPORTED ZIKA VIRUS IN HOUSTON, TEXAS Preventing Transmission Objectives Discuss the epidemiology of Zika virus Describe the Zika case investigation of the first confirmed case
More informationVaccine Hesitancy: Acceptance and demand of vaccines in the Americas
Vaccine Hesitancy: Acceptance and demand of vaccines in the Americas Desiree Pastor, MD, MPH Regional Immunization Advisor Immunization Unit Department of Family, Gender and Life Course PAHO/WHO Outline
More informationHEALTH ORGANIZATION HEALTH ORGANIZATION. regional committee. XLV Meeting. XXXVII Meeting Washington, D.C. September-October 1993
directing council regional committee HEALTH ORGANIZATION HEALTH ORGANIZATION XXXVII Meeting Washington, D.C. September-October 1993 XLV Meeting Provisional Agenda Item 5.3 CD37/11 (Eng.) 28 July 1993 ORIGINAL:
More informationHEALTH ORGANIZATION. ORGANIZATION XXXIX Meeting Washington, D.C. September 1996
directing council regional committee p )A PAN AMERICAN WORLD HEALTH HEALTH ORGANIZATION ORGANIZATION XXXIX Meeting Washington, D.C. September 1996 XLVIII Meeting Provisional Agenda Item 5.6 CD39/16 (Eng.)
More informationDeborah Chen MPH The Heart Foundation of Jamaica
Deborah Chen MPH The Heart Foundation of Jamaica The National Resuscitation Council Of Jamaica The Jamaica Coalition for Tobacco Control An alliance of organizations and individuals that collaborate to
More informationFOURTH ANNUAL VACCINATION WEEK IN THE AMERICAS (VWA 2006) FINAL REPORT
Immunization Unit Community and Family Health Area FOURTH ANNUAL VACCINATION WEEK IN THE AMERICAS (VWA 2006) FINAL REPORT 22-29 April 2006 Background Vaccination Week in the Americas (VWA) is an initiative
More informationr0 HEALTH HEALTH ORGANIZATION ORGANIZATION XXXIX Meeting Washington, D.C. September 1996 XLVIII Meeting Provisional Agenda Item 5.
directing council regional committee t PAN AMERICAN WORLD r0 HEALTH HEALTH ORGANIZATION ORGANIZATION XXXIX Meeting Washington, D.C. September 1996 XLVIII Meeting Provisional Agenda Item 5. 7 CD39/17 (Eng.)
More informationOverview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015
Overview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015 Ana F. Carvalho, MBA, MPH Director, Special Projects Vaccine Advocacy and Education Presented by: Jacqueline Lim
More informationHuman Papillomavirus and Related Cancers
Human Papillomavirus and Related Cancers Summary Report Update. September 15, 2010. AMERICAS - ii - Rights c WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) 2010 All rights
More informationThe successful case of HPV prophylactic vaccines
7th LA Congress of Clinical Research São Paulo, November 12, 2010 Brazilian Experience on Translational Medicine: The successful case of HPV prophylactic vaccines Luisa Lina Villa, Ph.D. Ludwig Institute
More informationVaccination legislation in Latin America and the Caribbean
Original Article Vaccination legislation in Latin America and the Caribbean Silas P. Trumbo a,carab.janusz b, *, Barbara Jauregui b, Mike McQuestion c, Gabriela Felix b,cuauhtémoc Ruiz-Matus b, Jon K.
More informationThe experience of national immunization. Challenges To Building Capacity For Evidence-Based New Vaccine Policy In Developing Countries
doi: 10.1377/hlthaff.2011.0361 HEALTH AFFAIRS 30, NO. 6 (2011): 1104 1112 2011 Project HOPE The People-to-People Health Foundation, Inc. By Jon Kim Andrus, Barbara Jauregui, Lúcia Helena De Oliveira, and
More informationWORLD HEALTH ORGANIZATION
WORLD HEALTH ORGANIZATION EXECUTIVE BOARD EB115/29 115th Session November 2004 Provisional agenda item 4.15 International Plan of Action on Ageing: report on implementation Report by the Secretariat 1.
More informationRegional Immunization Action Plan for the Americas Progress report 2015
Regional Immunization Action Plan for the Americas Progress report 2015 Introduction During the 54th Directing Council meeting of the Pan American Health Organization (PAHO) in September 2015, Member States
More informationINTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D. Akwatu Kenthi, MA Centre for Addictions and Mental Health CAMH
INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D Secretariat for Multidimensional Security FORTY-EIGHTH REGULAR SESSION December 6-8, 010 Washington, D.C. OEA/Ser.L/XIV..48 CICAD/doc.187/10 3 December
More informationHealth for All THE EXPANDED PROGRAM ON IMMUNIZATION IN THE AMERICAS: A REVIEW
l ABSTRACTS AND REPORTS 307 soon undertaken. This campaign relied principally on the media and community involvement. Media activities included the following: l A commercial firm was invited to prepare
More information144th SESSION OF THE EXECUTIVE COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 144th SESSION OF THE EXECUTIVE COMMITTEE Washington, D.C., USA, 22-26 June 2009 Provisional Agenda Item 4.17 CE144/22, Rev. 1 (Eng.) 11 June 2009
More informationEpidemiological Update Dengue
Situation summary in the Americas Epidemiological Update Dengue 22 February 2019 In the Region of the Americas, between epidemiological week (EW) 1 and EW 52 of 2018, a total of 560,586 cases of dengue
More information46th DIRECTING COUNCIL 57th SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 46th DIRECTING COUNCIL 57th SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 26-30 September 2005 Provisional Agenda Item 4.15 4 August
More informationMonitoring For Rotavirus Serotypes In The Americas. Jon Gentsch
Monitoring For Rotavirus Serotypes In The Americas Jon Gentsch Centers for Disease Control and Prevention, Atlanta, USA * The findings and conclusions in this presentation are those of the authors and
More informationMarta-Louise Ackers, a Robert E Quick, a Christopher J Drasbek, b Lori Hutwagner c and Robert V Tauxe a
O International Epldemiological Association 998 Printed in Great Britain International Journal of Epidemiology 998:27:-4 Are there national risk factors for epidemic cholera? The correlation between socioeconomic
More informationCE150/INF/6 (Eng.) Annex A A. SOCIAL DETERMINANTS OF HEALTH. Introduction
Annex A - 2 - A. SOCIAL DETERMINANTS OF HEALTH Introduction 1. World Health Assembly (WHA) Resolution WHA62.14 (2009), Reducing health inequities through action on the social determinants of health, urges
More information55th DIRECTING COUNCIL
55th DIRECTING COUNCIL 68th SESSION OF THE REGIONAL COMMITTEE OF WHO FOR THE AMERICAS Washington, D.C., USA, 26-30 September 2016 Provisional Agenda Item 7.4 15 August 2016 Original: English UPDATE ON
More information2010 Situation Analysis Elimination of Mother-to-child Transmission of HIV and Congenital Syphilis in the Americas
P O P S I E P A H O Elimination of Mother-to-child Transmission of HIV and Congenital Syphilis in the Americas RO S A LU T N O V M U N DI PAHO HQ Library Cataloguing-in-Publication Pan American Health
More informationUnderstanding the Roles of Different Bodies in Vaccine Decision Making: The Caribbean EPI Experience
Understanding the Roles of Different Bodies in Vaccine Decision Making: The Caribbean EPI Experience Prof J Peter Figueroa Department of Community Health & Psychiatry University of the West Indies Kingston,
More informationMain developments in past 24 hours
ECDC DAILY UPDATE Pandemic (H1N1) 2009 Update 02 October 2009, 09:00 hours CEST Main developments in past 24 hours Weekly Influenza Surveillance Overview to be published today; Media highlights and Eurosurveillance
More informationFERTILITY DECLINE AND PUBLIC POLICIES TO ADDRESS POPULATION RIGHTS: PERSPECTIVE FROM LATIN AMERICA
FERTILITY DECLINE AND PUBLIC POLICIES TO ADDRESS POPULATION RIGHTS: PERSPECTIVE FROM LATIN AMERICA Suzana Cavenaghi ENCE/IBGE, Brazil United Nations Expert Group Meeting on Fertility, Changing Population
More informationRegional Update EW 09 Influenza (March 15, h GMT; 12 h EST)
Regional Update EW 09 Influenza (March 15, 2011-17 h GMT; 12 h EST) The information presented in this update is based on data provided by Ministries of Health and National Influenza Centers of Member States
More information_flu.asp. region States. North. The Caribbean and. South. region. South
Regional Update EW 48, 2013 Influenza and other respiratory viruses (December 11, 2013) PAHO interactive influenza data: Uhttp://ais.paho.org/phip/viz/ed flu.asp Influenza Regional Reports: www.paho.org/reportesinfluenza
More informationImmunization Newsletter
Immunization Newsletter Pan American Health Organization Volume XXXV Number 4 Immunize and Protect Your Family August 2013 XXI Meeting of PAHO s Technical Advisory Group (TAG) on Vaccine-preventable Diseases:
More informationZika virus (ZIKV) Latin America & Caribbean Situation Report #11 15 February 2017
UNICEF/Ecuador/2016 Zika virus (ZIKV) Latin America & Caribbean Situation Report #11 15 February 2017 UNICEF/LACRO RESPONSE HIGHLIGHTS UNICEF has worked with government and non-government partners to ensure
More informationTECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE DISEASES BUENOS AIRES, ARGENTINA, 6-8 JULY 2011 FINAL REPORT
FINAL REPORT TECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE DISEASES BUENOS AIRES, ARGENTINA, 6-8 JULY 2011 FINAL REPORT TECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE DISEASES BUENOS AIRES, ARGENTINA,
More informationBuilding Zika preparedness in the Region of the Americas: research response
Update 23 September 2016 Building Zika preparedness in the Region of the Americas: research response Global Research Collaboration for Infectious Disease Preparedness meeting, Sao Paulo, November 30 Ludovic
More informationPAHO HIV REPORT. Progress of Implementation of the World Health Organization. Drug Resistance Strategy. in Latin America and the Caribbean:
OPS/FCH/HI/04-10.I PAHO HIV REPORT Progress of Implementation of the World Health Organization Drug Resistance Strategy in Latin America and the Caribbean: 2006 2009 June 2010 1 Progress of Implementation
More informationRegional Update EW 41 Influenza (October 25, h GMT; 12 h EST)
Regional Update EW 41 Influenza (October 2, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza
More informationPUBLIC HEALTH UPDATE
PUBLIC HEALTH UPDATE Eric C. McDonald, MD, MPH, FACEP Medical Director, Epidemiology and Immunizations Services, Public Health Services County of San Diego Health and Human Services Agency Annual SoCal
More informationAnnual Progress Report to IFPMA
Annual Progress Report to IFPMA November 2015 Women s Cancer Initiative in the Americas Contact: Areana Quiñones Director of Programs and Grants PAHO Foundation aquinones@pahofounda tion.org 1-202-974-3672
More informationDEMENTIA IN THE AMERICAS. CURRENT AND FUTURE COST AND PREVALENCE OF ALZHEIMER S DISEASE AND OTHER DEMENTIAs. bupa.com/dementia alz.co.
DEMENTIA IN THE AMERICAS CURRENT AND FUTURE COST AND PREVALENCE OF ALZHEIMER S DISEASE AND OTHER DEMENTIAs bupa.com/dementia alz.co.uk CONTENTS FOREWORD 3 about dementia 4 dementia in the americas 8 ABOUT
More informationRESEARCH ON AIDS IN LATIN AMERICA AND THE CARIBBEAN
ACHR 29/93.10 Original: Spanish RESEARCH ON AIDS IN LATIN AMERICA AND THE CARIBBEAN Division of Communicable Diseases Prevention and Control Program of AIDS and Sexually Transmitted Diseases July 1993.1..
More informationREGULA Initiative. Noncommunicable disease risk factors in the Americas: Considerations on the Strengthening of Regulatory Capacity
RGULA Initiative Noncommunicable disease risk factors in the Americas: Considerations on the trengthening of Regulatory Capacity Technical Reference Document ummary 2 NONCOMMUNICABL DIA IN TH AMRICA Distribution
More informationSaving Vaccines in the Americas: A Framework for Vaccine Safety Training
Saving Vaccines in the Americas: A Framework for Vaccine Safety Training Elizabeth K. Lutz, MPH Candidate Colorado School of Public Health Edwin J. Asturias, MD Director for Latin America, Center for Global
More informationCARIBBEAN SEMINAR ON TOBACCO AND TRADE
BOOKLET FOR PARTICIPANTS CARIBBEAN SEMINAR ON TOBACCO AND TRADE Accra Beach Hotel, Bridgetown, Barbados 18 May, 2017 II. Caribbean Subregional Seminar on Tobacco and Trade. Accra Beach Hotel, Bridgetown,
More informationAssessing the Health Policy Arena
resource from : conducting formative research for hpv vaccination program planning: practical experience from path publication title Assessing the Health Policy Arena publisher PATH publication date 2012
More informationXXVI CINP CONGRESS. mood disorders: The application. Gerhard Heinze M.D.
XXVI CINP CONGRESS CINP Task Force: Antidepressants and mood disorders: The application The impact of antidepressants and the treatment of depression in Latin America Gerhard Heinze M.D. Life expectancy
More information